Real-world evaluation of effectiveness, persistence, and usage patterns of monotherapy and combination therapy tofacitinib in treatment of rheumatoid arthritis in Australia

[1] Smolen JS(2016)Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 204 64-68

[2] Breedveld FC(2016)Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia Med J Aust 38 874-880

[3] Burmester GR(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis undefined undefined-undefined

[4] Hopkins AM(2017)Treatment with biologicals in rheumatoid arthritis: an overview Rheumatol Ther undefined undefined-undefined

[5] Proudman SM(2020)Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia Clin Rheumatol undefined undefined-undefined

[6] Vitry AI(2019)Using big data from real-world Australian rheumatology encounters to enhance clinical care and research Clin Exp Rheumatol undefined undefined-undefined

[7] Smolen JS(2015)AB0439 Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after food and drug administration approval: results from the corrona us rheumatoid arthritis registry Ann Rheum Dis undefined undefined-undefined

[8] Landewé RBM(2017)Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Lancet undefined undefined-undefined

[9] Bijlsma JWJ(2013)Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis Ann Rheum Dis undefined undefined-undefined

[10] Rein P(undefined)undefined undefined undefined undefined-undefined

[1] Smolen JS(2016)Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force Ann Rheum Dis 204 64-68

[2] Breedveld FC(2016)Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia Med J Aust 38 874-880

[3] Burmester GR(2020)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update Ann Rheum Dis undefined undefined-undefined

[4] Hopkins AM(2017)Treatment with biologicals in rheumatoid arthritis: an overview Rheumatol Ther undefined undefined-undefined

[5] Proudman SM(2020)Real-world evaluation of effectiveness, persistence, and usage patterns of tofacitinib in treatment of rheumatoid arthritis in Australia Clin Rheumatol undefined undefined-undefined

[6] Vitry AI(2019)Using big data from real-world Australian rheumatology encounters to enhance clinical care and research Clin Exp Rheumatol undefined undefined-undefined

[7] Smolen JS(2015)AB0439 Clinical characteristics of RA patients newly prescribed tofacitinib citrate (tofacitinib) in the United States after food and drug administration approval: results from the corrona us rheumatoid arthritis registry Ann Rheum Dis undefined undefined-undefined

[8] Landewé RBM(2017)Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial Lancet undefined undefined-undefined

[9] Bijlsma JWJ(2013)Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis Ann Rheum Dis undefined undefined-undefined

[10] Rein P(undefined)undefined undefined undefined undefined-undefined